Authors ’ Reply to Singh and Balasundaram: Comment on “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder”
(Source: CNS Drugs)
Source: CNS Drugs - November 4, 2022 Category: Neurology Source Type: research
Comment on: “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention Deficit/Hyperactivity Disorder”
(Source: CNS Drugs)
Source: CNS Drugs - November 4, 2022 Category: Neurology Source Type: research
Evaluation of a Rapid Topiramate Titration Scheme for the Early Detection of Cognitive Side Effects
ConclusionPhysicians might be able to detect adverse cognitive side effects sooner in epilepsy patients if TPM is administered using a faster titration rate while applying repeated cognitive assessments within days. This approach might help prevent any unnoticed intolerance and eventual negative consequences for the patient. Therefore, we recommend monitoring early on for adverse changes instead of withholding a potentially effective treatment option because of anticipated side effects. (Source: CNS Drugs)
Source: CNS Drugs - November 2, 2022 Category: Neurology Source Type: research
Dextromethorphan/Bupropion: First Approval
This article summarizes the milestones in the development of dextromethorphan/bupropion leading to this first approval for the treatment of adults with MDD. (Source: CNS Drugs)
Source: CNS Drugs - October 27, 2022 Category: Neurology Source Type: research
Clinical Effectiveness of Muscarinic Receptor-Targeted Interventions in Neuropsychiatric Disorders: A Systematic Review
ConclusionWhile the results are not definitive, findings on muscarinic receptor-targeted interventions in several mental disorders are promising in terms of efficacy and safety, specifically in treating schizophrenia, mood disorders, and behavioural and psychiatric symptoms of Alzheimer ’s disease. However, orthosteric muscarinic receptor-targeted interventions are associated with a range of peripheral adverse effects that are thought to be mediated via M2/M3 receptors. The orthosteric binding site of muscarinic acetylcholine receptors is remarkably conserved, posing a challenge for subtype-selective interventions; nonet...
Source: CNS Drugs - October 21, 2022 Category: Neurology Source Type: research
The Efficacy and Safety of Anti-CD20 Antibody Treatments in Relapsing Multiple Sclerosis: A Systematic Review and Network Meta-analysis
ConclusionsOverall, anti-CD20 antibody treatment is superior to a corresponding control in efficacy and safety measures and ocrelizumab and ofatumumab may be the most suitable anti-CD20 antibodies for treating relapsing multiple sclerosis. Additional large-scale and high-quality studies are still needed to further explore the safety of these therapies. (Source: CNS Drugs)
Source: CNS Drugs - October 16, 2022 Category: Neurology Source Type: research
The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study
ConclusionsAdverse events observed with long-term deutetrabenazine exposure were consistent with previous studies. Reductions in chorea persisted over time. Upon treatment cessation, there was no unexpected worsening of chorea.Clinical Trial RegistrationClinicalTrials.gov identifier: NCT01897896. (Source: CNS Drugs)
Source: CNS Drugs - October 15, 2022 Category: Neurology Source Type: research
Correction to: The Impact of Lithium on Brain Function in Bipolar Disorder: An Updated Review of Functional Magnetic Resonance Imaging Studies
(Source: CNS Drugs)
Source: CNS Drugs - October 7, 2022 Category: Neurology Source Type: research
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies
AbstractThe developmental and epileptic encephalopathies encompass a group of rare syndromes characterised by severe drug-resistant epilepsy with onset in childhood and significant neurodevelopmental comorbidities. The latter include intellectual disability, developmental delay, behavioural problems including attention-deficit hyperactivity disorder and autism spectrum disorder, psychiatric problems including anxiety and depression, speech impairment and sleep problems. Classical examples of developmental and epileptic encephalopathies include Dravet syndrome, Lennox –Gastaut syndrome and tuberous sclerosis complex. The ...
Source: CNS Drugs - October 4, 2022 Category: Neurology Source Type: research
Targeting d-Amino Acid Oxidase (DAAO) for the Treatment of Schizophrenia: Rationale and Current Status of Research
AbstractIn the brain,d-amino acid oxidase (DAAO) is a peroxisomal flavoenzyme. Through oxidative deamination by DAAO,d-serine, the main coagonist of synapticN-methyl-d-aspartate receptors (NMDARs), is degraded into α-keto acids and ammonia; flavin adenine dinucleotide (FAD) is simultaneously reduced to dihydroflavine-adenine dinucleotide (FADH2), which is subsequently reoxidized to FAD, with hydrogen peroxide produced as a byproduct. NMDAR hypofunction is implicated in the pathogenesis of schizophrenia. In pr evious studies, compared with control subjects, patients with schizophrenia had lowerd-serine levels in peripheral...
Source: CNS Drugs - October 4, 2022 Category: Neurology Source Type: research
Correction to: Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
(Source: CNS Drugs)
Source: CNS Drugs - October 3, 2022 Category: Neurology Source Type: research
Eslicarbazepine Acetate as Adjunctive Therapy for Primary Generalized Tonic-Clonic Seizures in Adults: A Prospective Observational Study
ConclusionsOur data suggest that ESL may provide additional benefits in the treatment of patients with PGTCS and motivate randomized controlled trials in this indication. (Source: CNS Drugs)
Source: CNS Drugs - September 30, 2022 Category: Neurology Source Type: research
Bruton ’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?
AbstractIn multiple sclerosis (MS) persisting disability can derive from acute relapses or, alternatively, from slow and steady deterioration, termed chronic progression. Emerging data suggest that the latter process occurs largely independent from relapse activity or development of new central nervous system (CNS) inflammatory lesions. Pathophysiologically, acute relapses develop as a consequence of de novo CNS infiltration of immune cells, while MS progression appears to be driven by a CNS-trapped inflammatory circuit between CNS-established hematopoietic cells as well as CNS-resident cells, such as microglia, astrocytes...
Source: CNS Drugs - September 30, 2022 Category: Neurology Source Type: research
Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) and Natalizumab Serum Concentration as Potential Biomarkers for Pharmacodynamics and Treatment Response of Patients with Multiple Sclerosis Receiving Natalizumab
ConclusionsSoluble vascular cell adhesion molecule 1 is a suitable pharmacodynamic marker during treatment with NTZ, which is significantly reduced already after the first dose, remains stable in individual patients even on extended interval dosing, and strongly correlates with NTZ SC. Because of the high inter-individual range, absolute levels of sVCAM-1 and NTZ SC are difficult to introduce as treatment monitoring biomarkers in order to predict disease activity in single patients. (Source: CNS Drugs)
Source: CNS Drugs - September 29, 2022 Category: Neurology Source Type: research
Psychotropic Drugs and Adverse Kidney Effects: A Systematic Review of the Past Decade of Research
ConclusionsDespite the heterogeneity of findings, owing to varying methodologies and research challenges, recent studies strongly suggest that lithium is associated with an increased risk of chronic kidney disease and nephrogenic diabetes insipidus, especially in older adults and long-term lithium users. Clinicians should balance the harms of lithium against its established benefits, and ensure adequate monitoring and management of comorbidities in all patients. Weaker evidence suggests that antiepileptics such as valproate and antipsychotics result in comparatively less harm to the kidney than lithium, but warrant monitor...
Source: CNS Drugs - September 26, 2022 Category: Neurology Source Type: research
